101555-61-7

Basic information

• Product Name: BOC-D-BETA-HOMOPHENYLALANINE
• Synonyms: BOC-(R)-3-AMINO-4-PHENYLBUTYRIC ACID;BOC-D-BETA-HOPHE-OH;BOC-D-BETA-HOMOPHENYLALANINE;BOC-D-BETA-HOMOPHE-OH;BOC-D-PHE-(C*CH2)OH;(R)-3-BOC-AMINO-4-PHENYLBUTYRIC ACID;(R)-3-TERT-BUTOXYCARBONYLAMINO-4-PHENYL-BUTYRIC ACID;N-BETA-T-BUTOXYCARBONYL-D-BETA-HOMOPHENYLALANINE
• CAS NO: 101555-61-7
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33
• Product Categories: β-Homo Amino Acids;Beta amino acids;pharmacetical;Amino Acid Derivatives;Pyridines
• Mol File: 101555-61-7.mol

Chemical Properties

• Boiling Point: 444.837 °C at 760 mmHg
• Flash Point: 222.829 °C
• Appearance: /
• Density: 1.139 g/cm³
• Vapor Pressure: 1.08E-08mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.43±0.10(Predicted)
• CAS DataBase Reference: BOC-D-BETA-HOMOPHENYLALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-BETA-HOMOPHENYLALANINE(101555-61-7)
• EPA Substance Registry System: BOC-D-BETA-HOMOPHENYLALANINE(101555-61-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• Hazardous Substances Data: 101555-61-7(Hazardous Substances Data)

Usage

Uses

Boc-D-β-homophenylalanine is used in the synthesis of dipeptidyl peptidase IV inhibitors.

InChI:InChI=1/C15H21NO4/c1-15(2,3)20-14(19)16-12(10-13(17)18)9-11-7-5-4-6-8-11/h4-8,12H,9-10H2,1-3H3,(H,16,19)(H,17,18)/t12-/m1/s1

Upstream product

• 106454-69-7 N-tert-butoxycarbonyl-D-Phenylalaninol 
• 126301-19-7 (2R)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropyl methanesulfonate 
• 186581-53-3 diazomethane 
• 18942-49-9 Boc-D-Phe-OH 
• 55177-35-0 (E)-4-phenyl-2-butenal 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 300-57-2 allylbenzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 131270-08-1 (R)-3-amino-4-phenylbutanoic acid 
• 228422-44-4 (R)-1-benzyl-3-hydroxypropylamine 
• 145149-49-1 (R)-tert-butyl (1-cyano-3-phenylpropan-2-yl)carbamate 
• 177839-89-3 (R)-tert-butyl 4-hydroxy-1-phenylbutan-2-ylcarbamate 
• 115313-19-4 1-diazo-3(R)-<<(1,1-dimethylethoxy)carbonyl>amino>-4-phenyl-2-butanone 

Downstream Products

• 115364-77-7 (R)-N-tert-butyloxycarbonyl-3-amino-4-phenyl-N'-(benzyloxy)-N'-methylbutanamide 
• 200949-32-2 N-[(2R)-1-carbamoyl-3-phenylpropan-2-yl]carbamic acid tert-butyl ester 
• 1236281-13-2 C₂₁H₂₅N₃O₅ 
• 115313-20-7 methyl 3-(R)-[N-(tert-butoxycarbonyl)amino]-4-phenylbutanoate 
• 145149-49-1 (R)-tert-butyl (1-cyano-3-phenylpropan-2-yl)carbamate 
• 1416469-35-6 tert-butyl [(2R)-4-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-4-oxo-1-phenylbutan-2-yl]carbamate 
• 1416467-81-6 4-[5-(cyclopropylmethoxy)-1,3-benzodioxol-4-yl]-N-[(2R)-4-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-4-oxo-1-phenylbutan-2-yl]-5H-pyrrolo[3,2-d]pyrimidine-7-carboxamide 
• 1416469-38-9 2-{1-[(3R)-3-amino-4-phenylbutanoyl]piperidin-4-yl}-6-(3,4-dimethoxyphenyl)-4,4-dimethyl-4,5-dihydropyridazin-3(2H)-one 
• 1416469-36-7 (4aS,8aR)-2-{1-[(3R)-3-amino-4-phenylbutanoyl]piperidin-4-yl}-4-(3,4-dimethoxyphenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one 

Relevant articles and documents

Concise synthesis of valuable chiral N-Boc-β-benzyl-β-amino acid via construction of chiral N-Boc-3-benzyl-5-oxoisoxazolidine through cross-metathesis/conjugate addition/oxidation

Valuable chiral N-Boc-β-benzyl-β-amino acid was concisely synthesized via construction of chiral N-Boc-3-benzyl-5-oxoisoxazolidine through cross-metathesis/conjugate addition/oxidation. All of the starting materials for the synthesis of chiral N-Boc-β-ben

Practical asymmetric synthesis of Sitagliptin phosphate monohydrate

Optically pure sitagliptin phosphate monohydrate is efficiently and practically synthesized through a chiral hemiacetal as the key intermediate in 54% overall yield starting from (E)-4-(2,4,5-trifluorophenyl)but-2-enal and N-boc-protected hydroxylamine. The chiral hemiacetal fragment is constructed by a tandem aza-Michael/hemiacetal reaction catalyzed by an organocatalyst and the influence of acidity of Br?nsted acid on tandem aza-Michael/hemiacetal reaction is researched in detail.

Synthesis method of chiral N-Boc-3-amino-4-aryl-butyric acid

The invention relates to a synthesis method of chiral N-Boc-3-amino-4-aryl-butyric acid. The method is as below: 1, conducting a cross metathesis reaction, an asymmetric conjugate addition reaction and an oxidation reaction on starting materials including an allyl aromatic compound and crotonaldehyde by a continuous reaction one-pot method to synthesize an N-Boc-3-aryl methyl-5-oxo isoxazole intermediate; or conducting an asymmetric conjugate addition reaction and an oxidation reaction on a starting material (E)-4-aryl-2-crotonaldehyde by a continuous reaction one-pot method to synthesize an N-Boc-3-aryl methyl-5-oxo isoxazole intermediate; and 2, subjecting (3R)-N-Boc-3-aryl methyl-5-oxo isoxazole intermediate by high-pressure hydrogenation to directly prepare the chiral N-Boc-3-amino-4-aryl-butyric acid. The synthesis method provided by the invention has the advantages of simple operation, mild reaction conditions, target product yield reaching 60-69%, and ee value of the target product reaching as high as 96%. The synthetic route has industrialization prospect.

SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administration of these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof as well as pharmaceutical compositions comprising said compounds as an active ingredient.

TAPP analogs containing β3-homo-amino acids: Synthesis and receptor binding

β-Amino acids containing α,β-hybrid peptides show great potential as peptidomimetics. In this paper, we describe the synthesis and affinity to μ-opioid and δ-opioid receptors of α,β-hybrids, analogs of the tetrapeptide Tyr- d-Ala-Phe-Phe-NH2 (TAPP). Each amino acid was replaced with an l- or d-β3-h-amino acid. All α,β-hybrids of TAPP analogs were synthesized in solution and tested for affinity to μ-opioid and δ-opioid receptors. The analog Tyr-β3h- d-Ala-Phe-PheNH2 was found to be as active as the native tetrapeptide.

Pharmaceutical compounds

The invention provides novel cryptophycin compounds which can be useful for disrupting the microtubulin system, as antineoplastic agents, antifungal, and for the treatment of cancer. The invention further provides a formulation for administering the novel cryptophycin compounds.

Syntheses and biological activities of bombesin analogs modified in the C-terminal dipeptide part

Bombesin receptor antagonists are possible therapeutic agents due to their ability to act as inhibitors of cellular proliferation. On the basis of our hypothesis on the mechanism of action of gastrin associating an activating enzyme system to the receptor and on the results reported in the litterature, we have synthesized bombesin analogues which have been modified in the C-terminal Leu13-Leu14 amide part. We have shown that modification in the C-terminal part of the bombesin strongly affected the biological activity in rat pancreatic acini. The most potent compound which is described here, H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Ψ/(CH2)Leu-NH2, was able to recognize the bombesin receptor on rat pancreatic acini (Ki 4.3 nM) and antagonized the bombesin stimulated amylase secretion (Ki 7.7 nM).

A novel approach to homochiral β-amino acids 1

An efficient synthesis of γ-aryl or alkyl substituted β-amino acids starting from N-Cbz-L-homoserine lactone via the formation of α-amino aryl, alkenyl or alkynyl ketones with the original α-carbon chirality retained as such is described. Copyright

Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes

Peptide retro-inverso modification was applied to the complete hydroxamate inhibitors of the three zinc metallopeptidases (neutral endopeptidase 24-11 (NEP, EC 3.4.24.11), aminopeptidase N (APN, EC 3.4.11.2), and a dipeptidylaminopeptidase (DAP) involved in the in vitro enkephalin degradation by brain tissues. Compounds corresponding to the general formula RN(OH)CO(CH2)(n)CH(CH2Ph)NHCOCH(R')COOH (n=0, 1) were synthesized. In the first series of inhibitors (n=0), the 'retro-inverso' modification induced a large decrease in inhibitory potency for NEP as compared to that of the parent compounds. In contrast, the presence of a methylene group between the hydroxamate and CHα in the second series (n=1) led to derivatives with inhibitory potencies in the nanomolar range, similar to their analogues with a natural amide bond. On the other hand, the retro-inverso modification led to a slight improvement in the inhibition of DAP and APN, in the first series of inhibitors, while the inverse result occurred in the second series. Thus, compounds containing an α-amino acid moiety in P'1 position behave as weak inhibitors of the three enzymes, with IC50 values in the micromolar range, and compounds bearing a β-amino acid moiety in the same position are more specific than the parent compounds for NEP inhibition.